ArticleBMC cancer2021

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.

Chunlong Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.